A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.
This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis.
The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline.
Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.
Inclusion Criteria:
Participant must be at least 12 years of age inclusive at the time of signing the informed consent.
Participated in an amlitelimab clinical trial for moderate to severe AD and received study treatment, adequately completed the assessments required for the treatment period.
Have reached the rollover timepoint to LTS17367 at the last visit of the treatment period of their feeder study SFY17915, INT18404, EFC17599, or EFC17600
Participants in DRI17366 must only be enrolled from 1 of the following 3 groups:
Participated in DRI17366 completing the previous study safety follow up (Week 68) and wish to re-initiate treatment with amlitelimab up to one year after the last visit
Complied with the previous clinical trial protocol to the satisfaction of the investigator
Body weight must be ≥25 kg
Provided signed informed assent/or consent and able to comply with the requirements of the protocol Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Developed a medical condition that would preclude participation as described in the section for permanent discontinuation of the feeder study or LTS17367 protocol
Known history of or suspected current significant immunosuppression, including history of invasive opportunistic infections or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration
History of solid organ or stem cell transplant
Any malignancies or history of malignancies prior to baseline (except for non-melanoma skin cancer that has been excised and completely cured for more than 5 years prior to baseline)
Participants positive for human immunodeficiency virus (HIV); participants with any of the following results at Screening (Visit 1) or at any point during the feeder study: presence of HBsAg with or without HBV DNA PCR test, or presence of anti-HBc Ab or presence of anti-HBs Ab with positive HBV DNA PCR test; positive HCVAb confirmed by positive HCV RNA PCR test
History (within last 2 years prior to baseline) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator
Participants with active TB, latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, non-TB mycobacterial infection, or who are at high risk of contracting TB (such as close contact with individuals with active or latent TB) or received Bacillus Calmette-Guérin (BCG)-vaccination within 12 weeks prior to screening
Participants with an indeterminate or a confirmed positive IGRA test are excluded from the study unless all of the following conditions are met:
Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease
Skin co-morbidity that would adversely affect the ability to undertake AD assessments (e.g., psoriasis, tinea corporis, lupus erythematosus) as per Investigator's judgment
Any medical condition which, in the opinion of the Investigator may present an unreasonable risk to the study participant as a result of his/her participation in this clinical study, may make participant's participation unreliable, or may interfere with study assessments
In the Investigator's opinion, medical conditions related to prior AD medications that have not healed/fully recovered for more than 2 weeks before screening visit, including, but not limited to, conjunctivitis, keratitis, eosinophilic conditions, arthralgia, herpes zoster, thrombosis
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Birmingham, Alabama 35209, United States
Birmingham, Alabama 35244, United States
Scottsdale, Arizona 85260, United States
Fremont, California 94538, United States
Lomita, California 90717, United States
Los Angeles, California 90045, United States
Wheat Ridge, Colorado 80033, United States
Boynton Beach, Florida 33436, United States
Fort Myers, Florida 33912, United States
Fort Myers, Florida 33919, United States
Jacksonville, Florida 32256, United States
Miami, Florida 33133, United States
Miami Lakes, Florida 33016, United States
St. Petersburg, Florida 33714, United States
Baton Rouge, Louisiana 70809, United States
Lafayette, Louisiana 70508, United States
Brighton, Massachusetts 02135, United States
Ypsilanti, Michigan 48197, United States
Ridgeland, Mississippi 39157, United States
East Windsor, New Jersey 08520, United States
New York, New York 10075, United States
Cincinnati, Ohio 45229, United States
Portland, Oregon 97239, United States
Philadelphia, Pennsylvania 19114, United States
Plymouth Meeting, Pennsylvania 19462, United States
Columbia, South Carolina 29204, United States
Columbia, South Carolina 29212, United States
Missouri City, Texas 77459, United States
Norfolk, Virginia 23502, United States
Vitória, Espírito Santo 29055-450, Brazil
Salvador, Estado de Bahia 41820-020, Brazil
Curitiba, Paraná 80230-130, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
Ribeirão Preto, São Paulo 14049-900, Brazil
Rio de Janeiro, 22241-180, Brazil
São Paulo, 04020-060, Brazil
São Paulo, 05403-000, Brazil
Bupyeong-Gu, Incheon-gwangyeoksi 21431, South Korea